Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 177

1.

Aurora kinase A mediates epithelial ovarian cancer cell migration and adhesion.

Do TV, Xiao F, Bickel LE, Klein-Szanto AJ, Pathak HB, Hua X, Howe C, O'Brien SW, Maglaty M, Ecsedy JA, Litwin S, Golemis EA, Schilder RJ, Godwin AK, Connolly DC.

Oncogene. 2014 Jan 30;33(5):539-49. doi: 10.1038/onc.2012.632. Epub 2013 Jan 21.

2.

Alisertib, an Aurora kinase A inhibitor, induces apoptosis and autophagy but inhibits epithelial to mesenchymal transition in human epithelial ovarian cancer cells.

Ding YH, Zhou ZW, Ha CF, Zhang XY, Pan ST, He ZX, Edelman JL, Wang D, Yang YX, Zhang X, Duan W, Yang T, Qiu JX, Zhou SF.

Drug Des Devel Ther. 2015 Jan 9;9:425-64. doi: 10.2147/DDDT.S74062. eCollection 2015.

3.

Inhibition of mitotic Aurora kinase A by alisertib induces apoptosis and autophagy of human gastric cancer AGS and NCI-N78 cells.

Yuan CX, Zhou ZW, Yang YX, He ZX, Zhang X, Wang D, Yang T, Wang NJ, Zhao RJ, Zhou SF.

Drug Des Devel Ther. 2015 Jan 14;9:487-508. doi: 10.2147/DDDT.S74127. eCollection 2015.

4.
5.

Dual inhibition of SRC and Aurora kinases induces postmitotic attachment defects and cell death.

Ratushny V, Pathak HB, Beeharry N, Tikhmyanova N, Xiao F, Li T, Litwin S, Connolly DC, Yen TJ, Weiner LM, Godwin AK, Golemis EA.

Oncogene. 2012 Mar 8;31(10):1217-27. doi: 10.1038/onc.2011.314. Epub 2011 Jul 25.

6.

Combination of Eribulin and Aurora A Inhibitor MLN8237 Prevents Metastatic Colonization and Induces Cytotoxic Autophagy in Breast Cancer.

Kozyreva VK, Kiseleva AA, Ice RJ, Jones BC, Loskutov YV, Matalkah F, Smolkin MB, Marinak K, Livengood RH, Salkeni MA, Wen S, Hazard HW, Layne GP, Walsh CM, Cantrell PS, Kilby GW, Mahavadi S, Shah N, Pugacheva EN.

Mol Cancer Ther. 2016 Aug;15(8):1809-22. doi: 10.1158/1535-7163.MCT-15-0688. Epub 2016 May 27.

7.

The aurora kinase A inhibitor MLN8237 enhances cisplatin-induced cell death in esophageal adenocarcinoma cells.

Sehdev V, Peng D, Soutto M, Washington MK, Revetta F, Ecsedy J, Zaika A, Rau TT, Schneider-Stock R, Belkhiri A, El-Rifai W.

Mol Cancer Ther. 2012 Mar;11(3):763-74. doi: 10.1158/1535-7163.MCT-11-0623. Epub 2012 Feb 1. Erratum in: Mol Cancer Ther. 2014 Nov;13(11):2765-6.

8.

The investigational Aurora kinase A inhibitor MLN8237 induces defects in cell viability and cell-cycle progression in malignant bladder cancer cells in vitro and in vivo.

Zhou N, Singh K, Mir MC, Parker Y, Lindner D, Dreicer R, Ecsedy JA, Zhang Z, Teh BT, Almasan A, Hansel DE.

Clin Cancer Res. 2013 Apr 1;19(7):1717-28. doi: 10.1158/1078-0432.CCR-12-2383. Epub 2013 Feb 12.

9.

Aurora kinase A has a significant role as a therapeutic target and clinical biomarker in endometrial cancer.

Umene K, Yanokura M, Banno K, Irie H, Adachi M, Iida M, Nakamura K, Nogami Y, Masuda K, Kobayashi Y, Tominaga E, Aoki D.

Int J Oncol. 2015 Apr;46(4):1498-506. doi: 10.3892/ijo.2015.2842. Epub 2015 Jan 22.

10.

HDM2 regulation by AURKA promotes cell survival in gastric cancer.

Sehdev V, Katsha A, Arras J, Peng D, Soutto M, Ecsedy J, Zaika A, Belkhiri A, El-Rifai W.

Clin Cancer Res. 2014 Jan 1;20(1):76-86. doi: 10.1158/1078-0432.CCR-13-1187. Epub 2013 Nov 15. Erratum in: Clin Cancer Res. 2015 Feb 1;21(3):661. Clin Cancer Res. 2015 Feb 1;21(3):661.

11.

Aurora kinase A promotes inflammation and tumorigenesis in mice and human gastric neoplasia.

Katsha A, Soutto M, Sehdev V, Peng D, Washington MK, Piazuelo MB, Tantawy MN, Manning HC, Lu P, Shyr Y, Ecsedy J, Belkhiri A, El-Rifai W.

Gastroenterology. 2013 Dec;145(6):1312-22.e1-8. doi: 10.1053/j.gastro.2013.08.050. Epub 2013 Aug 29.

12.

Targeting Aurora kinase-A downregulates cell proliferation and angiogenesis in neuroblastoma.

Romain C, Paul P, Kim KW, Lee S, Qiao J, Chung DH.

J Pediatr Surg. 2014 Jan;49(1):159-65. doi: 10.1016/j.jpedsurg.2013.09.051. Epub 2013 Oct 5.

13.

A MYC-aurora kinase A protein complex represents an actionable drug target in p53-altered liver cancer.

Dauch D, Rudalska R, Cossa G, Nault JC, Kang TW, Wuestefeld T, Hohmeyer A, Imbeaud S, Yevsa T, Hoenicke L, Pantsar T, Bozko P, Malek NP, Longerich T, Laufer S, Poso A, Zucman-Rossi J, Eilers M, Zender L.

Nat Med. 2016 Jul;22(7):744-53. doi: 10.1038/nm.4107. Epub 2016 May 23.

PMID:
27213815
14.

Aurora kinase targeting in lung cancer reduces KRAS-induced transformation.

Dos Santos EO, Carneiro-Lobo TC, Aoki MN, Levantini E, Bassères DS.

Mol Cancer. 2016 Feb 3;15:12. doi: 10.1186/s12943-016-0494-6.

15.

p53 deficiency enhances mitotic arrest and slippage induced by pharmacological inhibition of Aurora kinases.

Marxer M, Ma HT, Man WY, Poon RY.

Oncogene. 2014 Jul 3;33(27):3550-60. doi: 10.1038/onc.2013.325. Epub 2013 Aug 19.

PMID:
23955083
16.

An update on the pharmacokinetics and pharmacodynamics of alisertib, a selective Aurora kinase A inhibitor.

Durlacher CT, Li ZL, Chen XW, He ZX, Zhou SF.

Clin Exp Pharmacol Physiol. 2016 Jun;43(6):585-601. doi: 10.1111/1440-1681.12571. Review.

PMID:
26999067
17.

Alisertib (MLN8237), a selective Aurora-A kinase inhibitor, induces apoptosis in human tongue squamous cell carcinoma cell both in vitro and in vivo.

Qi L, Zhang Y.

Tumour Biol. 2015 Mar;36(3):1797-802. doi: 10.1007/s13277-014-2782-3. Epub 2014 Nov 4.

PMID:
25366143
18.

The mitotic kinase Aurora--a promotes distant metastases by inducing epithelial-to-mesenchymal transition in ERα(+) breast cancer cells.

D'Assoro AB, Liu T, Quatraro C, Amato A, Opyrchal M, Leontovich A, Ikeda Y, Ohmine S, Lingle W, Suman V, Ecsedy J, Iankov I, Di Leonardo A, Ayers-Inglers J, Degnim A, Billadeau D, McCubrey J, Ingle J, Salisbury JL, Galanis E.

Oncogene. 2014 Jan 30;33(5):599-610. doi: 10.1038/onc.2012.628. Epub 2013 Jan 21.

19.

The role of p27(Kip1) in dasatinib-enhanced paclitaxel cytotoxicity in human ovarian cancer cells.

Le XF, Mao W, He G, Claret FX, Xia W, Ahmed AA, Hung MC, Siddik ZH, Bast RC Jr.

J Natl Cancer Inst. 2011 Sep 21;103(18):1403-22. doi: 10.1093/jnci/djr280. Epub 2011 Aug 2.

20.

Preclinical pharmacokinetic/pharmacodynamic/efficacy relationships for alisertib, an investigational small-molecule inhibitor of Aurora A kinase.

Palani S, Patel M, Huck J, Zhang M, Balani SK, Yang J, Chen S, Mettetal J, Manfredi M, Shyu WC, Ecsedy JA, Chakravarty A.

Cancer Chemother Pharmacol. 2013 Dec;72(6):1255-64. doi: 10.1007/s00280-013-2305-8. Epub 2013 Oct 8.

PMID:
24101146

Supplemental Content

Support Center